HCW Biologics Inc., a clinical-stage biopharmaceutical company, announced the pricing of its follow-on offering amounting to approximately $5.0 million. The offering includes 671,140 units priced at $7.45 per unit, each consisting of one share of common stock and two warrants to purchase additional shares. The warrants are exercisable immediately and expire five years from issuance. The company plans to use the proceeds for clinical development, business development, and other corporate purposes. Additionally, the exercise price of certain existing warrants has been reduced from $41.20 to $7.45 per share. Maxim Group LLC is the sole placement agent for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.